DBV Technologies S.A. (EPA:DBV)
3.036
-0.014 (-0.46%)
Jun 3, 2026, 5:35 PM CET
DBV Technologies Revenue
DBV Technologies had revenue of $900.00K USD in the quarter ending March 31, 2026, with 12.50% growth. This brings the company's revenue in the last twelve months to $5.14M, up 69.44% year-over-year. In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth.
Revenue (ttm)
$5.14M
Revenue Growth
+69.44%
P/S Ratio
181.42
Revenue / Employee
$31.92K
Employees
161
Market Cap
902.54M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 156.33M |
| Genfit | 65.43M |
| Cellectis | 65.14M |
| Nanobiotix | 32.59M |
| MedinCell | 32.44M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
DBV Technologies News
- 2 hours ago - DBV Technologies Announces the Results of its 2026 Combined General Meeting - GlobeNewsWire
- 23 hours ago - DBV Technologies S.A.: DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy - Finanz Nachrichten
- 23 hours ago - DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy - GlobeNewsWire
- 23 hours ago - DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy - Wallstreet:Online
- 14 days ago - Artisan Partners Limited Partnership Reduces Stake in DBV Technologies SA - GuruFocus
- 15 days ago - DBV Technologies Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 21 days ago - DBV Technologies S.A.: Combined General Meeting of June 3, 2026 - Finanz Nachrichten
- 21 days ago - Combined General Meeting of June 3, 2026 - GlobeNewsWire